Koka Rima, Bade Najeebah A, Sausville Edward A, Ning Yi, Zou Ying
Department of Pathology, University of Maryland School of Medicine Baltimore, 22 S. Greene St NBW53, Baltimore, MD 21201 USA.
University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD USA.
Mol Cytogenet. 2017 Oct 26;10:39. doi: 10.1186/s13039-017-0340-6. eCollection 2017.
ABL1 gene translocations can be seen in precursor T-acute lymphoblastic leukemia (T-ALL). The typical translocation partner is the NUP214 gene. BCR-ABL translocations are relatively rare in this entity. Furthermore, while there have been unique patterns of amplification noted among the NUP214-ABL fusion genes, there have been few such reports among cases with BCR-ABL fusion genes.
Here we report a unique case of a 44-year old patient with T-ALL in which the blasts demonstrated a derivative chromosome 9 involving a 9;22 translocation and a dicentric Philadelphia chromosome 22 with a homogeneously staining region at the interface of the 9;22 translocation, leading to BCR-ABL1 gene amplification. Fluorescence in-situ hybridization (FISH) showed abnormal BCR/ABL1 fusions with the BCR-ABL1 gene amplification in 48% of the interphase cells analyzed. The translocation was confirmed by SNP array.
We present a novel derivative chromosome 9 that shows BCR-ABL gene fusion along with a dicentric Philadelphia chromosome 22 with BCR-ABL1 gene amplification. This is a unique pattern of BCR-ABL fusion which has never been described in T-ALL. It is significant that the patient responded to standard treatment with the CALGB 10403 protocol and supplementation with a tyrosine kinase inhibitor. Identification of additional patients with this pattern of BCR-ABL fusion will allow for enhanced risk assessment and prognostication.
ABL1基因易位可见于前体T淋巴细胞白血病(T-ALL)。典型的易位伙伴是NUP214基因。BCR-ABL易位在该疾病中相对少见。此外,虽然在NUP214-ABL融合基因中已发现独特的扩增模式,但关于BCR-ABL融合基因病例的此类报道很少。
我们在此报告一例独特的44岁T-ALL患者,其原始细胞显示一条衍生的9号染色体,涉及9;22易位,以及一条双着丝粒的费城染色体22,在9;22易位界面处有一个均匀染色区,导致BCR-ABL1基因扩增。荧光原位杂交(FISH)显示,在分析的48%的间期细胞中存在异常的BCR/ABL1融合以及BCR-ABL1基因扩增。该易位通过单核苷酸多态性(SNP)阵列得到证实。
我们展示了一条新的衍生9号染色体,其显示BCR-ABL基因融合以及一条带有BCR-ABL1基因扩增的双着丝粒费城染色体22。这是一种独特的BCR-ABL融合模式,在T-ALL中从未被描述过。重要的是,该患者对CALGB 10403方案的标准治疗以及酪氨酸激酶抑制剂补充治疗有反应。识别更多具有这种BCR-ABL融合模式的患者将有助于加强风险评估和预后判断。